Quickly sort and find the exact file you need here. Send the files directly into your Shareholder Briefcase or read and right click "save target as" individual files.
|OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2016||Nov 10, 2016||21.2 KB|
|3Q 2016 10-Q||Nov 10, 2016||500.8 KB|
|OncoGenex to Report Third Quarter 2016 Financial Results on Nov. 10, 2016||Nov 3, 2016||9.8 KB|
|OncoGenex Announces Results from the Phase 3 ENSPIRIT Trial of Custirsen in Non-Small Cell Lung Cancer||Oct 13, 2016||14.8 KB|
|OncoGenex Announces Results from the Phase 3 AFFINITY Trial of Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer||Aug 16, 2016||16.0 KB|
|2Q 2016 10-Q||Aug 4, 2016||470.3 KB|
|Q1 2016 10-Q||May 12, 2016||440.4 KB|
|2015 Proxy||Mar 21, 2016||432.6 KB|
|2015 10-K||2016||767.0 KB|
|Charter of the Audit Committee||97.1 KB|
- Corporate Governance
- Management & Board
- Stock Information
- SEC Filings
- Quarterly Results
- Analyst Coverage
- Webcasts & Presentations
- Scientific Publications & Presentations
- Frequently Asked Questions
© 2004-2017 OncoGenex Pharmaceuticals Inc. All rights reserved.
OncoGenex product candidates are investigational drugs for use only in approved clinical trials.
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.
OncoGenex is uniquely focused on the challenge of cancer treatment resistance. We currently have several on-going clinical trials that may be of interest to you.
OncoGenex focuses on diverse molecular entities that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.
OncoGenex develops novel compounds designed to meet the persistent challenge of treatment resistance across a variety of cancers.